论文部分内容阅读
目的分析急性脑梗死患者行氯吡格雷联合前列地尔药物治疗的效果。方法 50例急性脑梗死患者,依据抽签的方法分为实验组和参照组,每组25例,其中参照组患者行氯吡格雷治疗,实验组在此基础上加行前列地尔药物治疗,对比两组患者的临床治疗效果、美国国立卫生研究院卒中量表(NIHSS)评分以及不良反应发生情况。结果实验组总有效率96.00%高于参照组的76.00%,差异具有统计学意义(P<0.05)。治疗前,实验组NIHSS评分为(9.6±2.0)分,参照组为(9.8±2.1)分,组间对比差异无统计学意义(t=0.3448,P>0.05);治疗后,实验组NIHSS评分为(3.0±1.2)分,低于参照组的(7.6±1.7)分,差异具有统计学意义(t=11.0531,P<0.05)。两组治疗后NIHSS评分均低于治疗前,差异具有统计学意义(P<0.05)。实验组与参照组不良反应发生率(20.00%VS 28.00%)比较差异无统计学意义(P>0.05)。结论将氯吡格雷联合前列地尔应用于急性脑梗死中,其治疗效果显著,能够有效对患者的神经功能进行改善,这对于临床研究具有重要作用。
Objective To analyze the effect of clopidogrel combined with alprostadil in patients with acute cerebral infarction. Methods Fifty patients with acute cerebral infarction were randomly divided into experimental group and reference group according to the method of lottery, with 25 cases in each group. The patients in the reference group were treated with clopidogrel. The experimental group was treated with alprostadil, Clinical outcomes in both groups, NIH Stroke Scale (NIHSS) score, and adverse events. Results The total effective rate in experimental group was 96.00% higher than 76.00% in reference group, the difference was statistically significant (P <0.05). Before treatment, the NIHSS score of the experimental group was (9.6 ± 2.0) points and the reference group was (9.8 ± 2.1) points, there was no significant difference between the two groups (t = 0.3448, P> 0.05) (3.0 ± 1.2), lower than the reference group (7.6 ± 1.7) points, the difference was statistically significant (t = 11.0531, P <0.05). NIHSS scores after treatment were lower than before treatment, the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the experimental group and the reference group (20.00% VS 28.00%) (P> 0.05). Conclusion The application of clopidogrel combined with alprostadil in acute cerebral infarction has significant therapeutic effect and can effectively improve the neurological function of patients, which plays an important role in clinical research.